Leila Su

Title: Leila Su: Innovator in Chronic Myelogenous Leukemia Research

Introduction

Leila Su is a prominent inventor based in Diamond Bar, California, known for her significant contributions to the field of cancer research. With a total of four patents to her name, she has made strides in understanding and combating chronic myelogenous leukemia (CML). Her innovative approaches have the potential to change the landscape of treatment for this challenging disease.

Latest Patents

One of Leila Su's latest patents focuses on a cell culture model for acquired chemoresistance of chronic myelogenous leukemia. This patent outlines a method for generating a CML acquired chemoresistant culture model. The process involves providing a naïve blast crisis CML cell line, administering a mutation-inducing dose of imatinib, and maintaining the culture until the treated cell line relapses. The repopulated cell culture is then identified as a CML acquired chemoresistant cell line by detecting a BCR-ABL mutation, which is crucial for understanding the mechanisms of resistance.

Career Highlights

Leila Su is currently affiliated with City of Hope, a leading research and treatment center. Her work at this institution has allowed her to focus on innovative research that addresses critical challenges in cancer treatment. Her dedication to advancing medical science is evident in her research and patent contributions.

Collaborations

Leila has collaborated with esteemed colleagues, including Yate-Ching Yuan and Yun Yen. These partnerships have fostered a collaborative environment that enhances the research efforts at City of Hope.

Conclusion

Leila Su's work in the field of chronic myelogenous leukemia research exemplifies her commitment to innovation and improving patient outcomes. Her patents and collaborations highlight her role as a key figure in advancing cancer research.